Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

311 total trials 202 currently recruiting 73 completed

Trial Pipeline

RECRUITING Phase 2

Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response

NCT07142551

RECRUITING Phase 2

Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)

NCT07209189

RECRUITING NA

Physician- and Patient-based Barriers to NGS Testing

NCT07209176

RECRUITING NA

Patient Navigation Program to Improve Clinical Trial Enrollment in Cancer Patients

NCT06138067

RECRUITING

Pediatric Radiation Therapy Registry

NCT07129317

RECRUITING NA

Exercise in Prostate Cancer

NCT06165302

RECRUITING Phase 1

A Clinical Trial to Assess PVX7 Immunotherapy Regimens in Advanced Cervical Cancer Patients

NCT06315257

RECRUITING Phase 2

NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer

NCT06941857

RECRUITING Phase 2

The COSMYC Trial (COmbined Suppression of MYC)

NCT06922318

RECRUITING Phase 1

KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer

NCT06411691

RECRUITING NA

7-Days Water-Only Fasting Trial in Prostate Cancer

NCT06826924

RECRUITING Phase 1

Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

NCT06564623

RECRUITING Phase 1

Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer

NCT06782932

RECRUITING NA

Proton SBRT for Spinal Metastasis

NCT06895564

RECRUITING Early Phase 1

Feasibility of CSF and Plasma ctDNA in BRAF-altered Glioma During Treatment With Plixorafenib

NCT06610682

RECRUITING NA

Standard-of-Care Reduced-Intensity Conditioning (RIC) With 200 Versus 400 cGy of Total Body Irradiation (TBI) in Patients With Acute Leukemia Undergoing First Allogeneic Blood or Marrow Transplantation (BMT)

NCT06803745

RECRUITING NA

Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma

NCT06796543

RECRUITING Phase 2

Stereotactic Body Proton Therapy for Treatment of Primary Renal Cell Carcinoma

NCT06376669

RECRUITING Phase 2

Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer

NCT06616597

RECRUITING Phase 2

Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer

NCT06617923

RECRUITING

SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization

NCT06389097

RECRUITING

Study in Patients With Breast Cancer Leptomeningeal Metastasis

NCT06638294

RECRUITING Phase 2

Renal Retention in High Grade Upper Tract Urothelial Cancer

NCT05656235

RECRUITING Early Phase 1

Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

NCT06398457

RECRUITING NA

Gut Microbiome, Adverse Effects, and Markers Through MEtabolic Reprogramming

NCT06536881

RECRUITING Phase 2

Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers

NCT06001658

RECRUITING NA

Behavioral Weight Loss for Cancer Survivors in Maryland: A Trial With Adaptive Interventions

NCT06463249

RECRUITING

Exploration of Personalized Biomarkers During Neoadjuvant Radiation Therapy for Spinal and Sacral Chordoma

NCT06463262

RECRUITING Phase 2

Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer

NCT06205836

RECRUITING Phase 1

Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC

NCT05950139

RECRUITING Phase 2

PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC

NCT06245889

RECRUITING NA

Pre-operative Hypofractionated Proton Therapy

NCT05917301

RECRUITING Phase 2

Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer

NCT06014255

RECRUITING Phase 1

DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

NCT06027086

RECRUITING Phase 2

Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).

NCT05977907

RECRUITING Phase 1

Safety and Efficacy of Allogeneic HPV-specific T Cells in Adults With Recurrent or Metastatic HPV16+ Cancers

NCT04713046

RECRUITING Phase 2

Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

NCT06059118

RECRUITING Early Phase 1

Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT

NCT03861676

RECRUITING NA

Cognitive Outcomes After Brain Substructure-informed Radiation Planning in Pediatric Patients

NCT05658731

RECRUITING

Liquid Biopsy-informed Precision Oncology Study to Evaluate Utility of Plasma Genomic Profiling for Therapy Selection

NCT05585684

RECRUITING Phase 1

KRAS-Targeted Vaccine With Nivolumab and Ipilimumab for Patients With NSCLC

NCT05254184

RECRUITING Phase 1

Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma

NCT05083754

RECRUITING Phase 2

Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer

NCT05312671

RECRUITING NA

Cardiometabolic Screening Program

NCT05386719

RECRUITING Phase 1

Intraoperative Radiation Therapy After Stereotactic Body Radiation Therapy and Chemotherapy in Treatment of Pancreatic Adenocarcinoma

NCT05141513

RECRUITING Phase 2

Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT04704505

RECRUITING Phase 1

Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer

NCT05013216

RECRUITING Phase 1

Study of 111In-XYIMSR-01 SPECT/CT in Patients With Metastatic Clear Cell Renal Cell

NCT07062549

RECRUITING Phase 2

Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w/HPV H&N Ca

NCT04988074

RECRUITING Phase 2

Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.

NCT04753879

RECRUITING Phase 1

Combination Radiotherapy and Radiopharmaceutical Therapy Treatment Planning for Thyroid Cancer

NCT04892303

RECRUITING Phase 1

HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia

NCT04131413

RECRUITING Phase 2

Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression

NCT04363164

RECRUITING Phase 1

DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma

NCT04248569

RECRUITING

Proton Radiation Therapy Registry

NCT04376229

RECRUITING Phase 2

Regenerative Medicine to Restore Hematopoiesis and Immune Function in Immunodeficiencies and Inherited Bone Marrow Failures

NCT04232085

RECRUITING Phase 2

Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations

NCT03786796

RECRUITING Phase 2

Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma

NCT03521830

RECRUITING Phase 1

Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma

NCT03465592

RECRUITING NA

Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

NCT03223922

RECRUITING NA

Image-Guided Gynecologic Brachytherapy

NCT02993900

RECRUITING

Immunobiology Blood and Tissue Collection of Upper Aerodigestive Malignancies

NCT05995821

RECRUITING Phase 2

Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

NCT01804634

ACTIVE NOT RECRUITING Phase 1

Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML

NCT05716009

ACTIVE NOT RECRUITING Phase 1

Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients

NCT05823571

ACTIVE NOT RECRUITING Phase 2

Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer

NCT05014776

ACTIVE NOT RECRUITING NA

Proton Pencil Beam Scanning GRID for Treatment of Bulky Tumors

NCT05121545

ACTIVE NOT RECRUITING Phase 1

Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)

NCT04658147

ACTIVE NOT RECRUITING Phase 2

Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca

NCT04848116

ACTIVE NOT RECRUITING

Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM)

NCT04447651

ACTIVE NOT RECRUITING Phase 2

Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma

NCT04209686

ACTIVE NOT RECRUITING Phase 2

Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer

NCT04386746

ACTIVE NOT RECRUITING Phase 1

Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer

NCT04117087

ACTIVE NOT RECRUITING Phase 1

Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM

NCT03961971

ACTIVE NOT RECRUITING Phase 2

Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma

NCT03918252

ACTIVE NOT RECRUITING Phase 1

Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors

NCT03875287

ACTIVE NOT RECRUITING Phase 1

REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer

NCT03610711

ACTIVE NOT RECRUITING Phase 2

Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor

NCT03607890

ACTIVE NOT RECRUITING Phase 2

Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer

NCT03573648

ACTIVE NOT RECRUITING Phase 2

Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC

NCT03439735

ACTIVE NOT RECRUITING Phase 2

Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer

NCT03471650

ACTIVE NOT RECRUITING NA

Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins

NCT02965755

ACTIVE NOT RECRUITING Phase 1

A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance

NCT03114865

ACTIVE NOT RECRUITING Phase 1

Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer

NCT03044613

ACTIVE NOT RECRUITING Phase 2

Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder

NCT02845323

ACTIVE NOT RECRUITING Phase 1

Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma

NCT02989636

ACTIVE NOT RECRUITING Phase 2

Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis

NCT03047135

ACTIVE NOT RECRUITING Phase 2

Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer

NCT02923180

ACTIVE NOT RECRUITING Phase 2

Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor

NCT02738866

ACTIVE NOT RECRUITING

Monitoring Plasma Tumor DNA in Early-Stage Breast Cancer

NCT02743910

ACTIVE NOT RECRUITING Phase 2

Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer

NCT02452008

ACTIVE NOT RECRUITING Phase 2

Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas

NCT02451982

ACTIVE NOT RECRUITING Phase 2

Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC

NCT02259621

ACTIVE NOT RECRUITING Phase 2

Subventricular Zone (SVZ) and Temozolomide in Glioblastoma Multiforme

NCT02177578

ACTIVE NOT RECRUITING Phase 2

Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer

NCT01937117

ACTIVE NOT RECRUITING NA

MRI for Assessing Prostate Cancer Response

NCT01607008

ACTIVE NOT RECRUITING Phase 2

Boost GVAX Pancreas Vaccine With or Without CY in Patients With Pancreas Cancer

NCT01088789

ACTIVE NOT RECRUITING

Johns Hopkins Breast Cancer Program Longitudinal Repository

NCT01937039

ACTIVE NOT RECRUITING Phase 2

Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer

NCT00616967

COMPLETED Phase 2

Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma

NCT04301778

What the Pipeline for Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Shows

According to the ClinicalTrials.gov registry, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins is linked to 311 US clinical trials across every stage of research activity. Of those, 202 studies are currently recruiting — about 65% of the sponsor's indexed portfolio — and 73 are already marked complete, representing roughly 23% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.

The phase mix for Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins reports 1 late-stage studies (Phase 3 and Phase 4 combined) and 238 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.

The top therapeutic focus area indexed for Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins is Prostate Cancer with 17 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial